CME Sessions at EANM’11

EANM’11 – CME Session XI

CME Session XI – ESNM Faculty (Interactive)
October 18, 2011, 14:30 – 16:00
Diagnostic Imaging of Neuroendocrine Tumours

Moderator: L. Mansi (Naples)


Cases presented by:
D. Yu (London):
Latest Advances in the Use of CT and MRI in Neuroendocrine Tumours
J. Buscombe (Cambridge):
Single Photon Imaging of Neuroendocrine Tumours in 2011
D. Wild (Freiburg):
PET Imaging in Neuroendocrine Tumours


Educational objectives:

  1. Understand the latest methods used in CT and MRI to identify primary and secondary neuroendocrine tumours.
  2. Know the benefits and limitations of In-111 pentetreotide imaging in neuroendocrine tumours and how SPECT-CT can affect results
  3. Understand when other single photon techniques may be of use including I-123 MIBG, bone scintigraphy and Tc-99m peptides
  4. Know the relationship between positivity of different somatostatin analogues labelled with Ga-68 and different types of neurendocrine tumours
  5. Understand the role of new tracers such as F-18 DOPA and the role of F-18 FDG in predicting prognosis in neuroendocrine tumours
  6. Understand how both anatomical and functional imaging allows access to personalized medicine for the patients suffering form a neuroendocrine tumour


Summary:

Nuclear medicine has become the essential diagnostic method used to stage neuroendocrine tumours and re-evaluate the response of these tumours to treatment. However there have also been advances in the morphological imaging of these tumours using latest techniques in CT and MRI. This presentation is concerned on how both radiological and scintigraphic techniques can be combined to improve the quality of information gained by imaging in these patients. New scintigraphic techniques include the use of SPECT-CT to improve both the sensitivity and specificity of standard techniques such as In-111 pentetreotide and newer radiopharmaceuticals such as Tc-99m DOTANOC and Tc-99m DOTATATE. PET techniques have enabled more about the molecular functioning of these tumours to be assessed for example with Ga-68 labelled somatostatin analogues, the use of F-18 DOPA and F-18 FDG and what the results of these studies mean for the patient.
All this information is combined to provide therapy to produce the best possible effect in a clear example of personalized medicine.


Key Words:

In-111 Pentetreotide, Neuroendocrine Tumour SPECT/CT, Ga-68 DOTATATE, PET/CT

This website uses cookies. Learn more